^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:trastuzumab envedotin (DP303c) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    DP303c in Patients With HER2-positive Advanced Breast Cancer

    Excerpt:
    ...Confirmed to be HER2 positive by central lab (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive); 5....
    Trial ID:
    NCT05901935
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    385MO - A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

    Published date:
    10/16/2023
    Excerpt:
    Among 66 efficacy evaluable pts with BC, ORR and DCR were 51.5% (95%CI: 38.9-64.0) and 77.3% (95%CI: 65.3-86.7). The median PFS and DoR were 6.44 mo (95%CI: 4.14-8.51) and 10.97 mo (95%CI: 3.98-NA) for all 68 pts with BC...DP303c demonstrated promising anti-tumor activity with acceptable safety in pts with pre-treated advanced solid tumors, especially BC.
    Trial ID:
    NCT04146610